Endo Pharmacauticals has discontinued Collagenase Clostridium Histolyticum (CCH) injection

by andromedical Andropenis® penis extender increases Penis Length

Endo Pharmacauticals has discontinued Collagenase Clostridium Histolyticum (CCH) injection in Australia and Asia, and plans to do the same to whole Europe by the end of 2019.

The American laboratory has decided to withdraw it for economic reasons. As a result, the drug is no longer available except in the US and Canada. Now the only treatment options for Peyronie´s disease are surgery or Penile Traction Device (alone or combined with PRP), in the rest of the world. See official letter

Dear Healthcare Professional

This letter is to inform you that the company will discontinue the commercialisation of X.... by the end of 2019.

X..... is a product owned by E.....’). Currently, X.... is commercialised in the EU and other European and Middle Eastern countries by the company We have agreed to terminate the cooperation agreement for X.... effective December 31, 2019. The decision to withdraw is not based on safety or efficacy concerns.

the company are committed to managing the de-registration of X.... from the territories in an ethical and transparent manner and it will process the withdrawal of the EU Marketing Authorisation, which will be effective from 1 March, 2020.

Please be assured that the wellbeing of patients during the discontinuation process is of paramount importance and we are committed to the safety and comfort of all patients during the process of transition to other therapies. We want to emphasize that, subject to product availability from our supplier, Sobi is committed to providing X...... up until the end of 2019.

We would like to thank you for your interest in X...... over the years and deeply regret any inconvenience this may cause you.

If you have any questions or concerns, please do not hesitate to contact us at your convenience.

After de-registration, all enquiries, questions or requests for Named Patient Use of X..... must be referred directly

Yours Sincerely,

Business Unit Director